Clinical Trial Update: A Multiple Dose Study Of PF-04950615 (RN316) In Subjects On Maximum Doses Of Statins [Phase 2]

View source ↗

Summary

Pfizer completed a Phase 2 multiple-dose study of PF-04950615 (RN316) in patients on maximum statin therapy to evaluate lipid effects, with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Dyslipidemia
• Hypercholesterolemia

Drugs mentioned

• PF-04950615 (RN316) (PF-04950615)

Snippet

Sponsor: Pfizer | Conditions: Hypercholesterolemia, Dyslipidemia | Phase 2 | Status: COMPLETED | Results posted: 2017-11-08